Clinical-stage biotech Avidity Biosciences (NASDAQ: RNA) had some good news to report toward the end of this week, and investors rewarded it by piling into the company's stock. By the close of trading ...

(Reuters) -Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported on Wednesday, citing people familiar with the matter.

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based Duchenne muscular dystrophy (DMD) candidate. In a phase 1/2 trial, most adverse ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Avidity Biosciences, Inc. (NASDAQ:RNA) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE program in Facioscapulohumeral Muscular ...

Swiss drugmaker Novartis on Sunday said it agreed to acquire US biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare ...

The buyout of one biotechnology company can sometimes hurt the shares of its competitors, as investors may feel like they picked the wrong merger candidate. But not in the case for those who bought ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against ...

Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Avidity Biosciences (RNA). The reason why I want to go over this biotech next is because it is ...

A big premium paid to acquire Avidity Biosciences is bolstering the merger case for Dyne Therapeutics, analyst says Dyne Therapeutics' stock sees record rally, but one analyst says it could still ...